Roche Holding AG (RHHBY)
Chart Events
Performance Outlook
| Previous Close | 46.82 |
| Open | 46.36 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 45.88 - 46.40 |
| 52 Week Range | 39.72 - 51.05 |
| Volume | 1,824,467 |
| Avg. Volume | 1,073,485 |
| Market Cap | 323.695B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 20.87 |
| EPS (TTM) | 2.21 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.22 (2.61%) |
| Ex-Dividend Date | Mar 18, 2021 |
| 1y Target Est | 52.44 |
Fair Value
Related Research
- ROCHE HOLDINGS AGAnalyst Report: Roche Holding AGRoche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 60% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.RatingFair ValueEconomic Moat5 days agoMorningstar
- GlobeNewswire
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a mon
- GlobeNewswire
Roche opens access to pathology imaging tools to improve patient care
Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analysis tools Artificial intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatmentOpen digital pathology environments can break down barriers to allow for rapid technology advances across industry
- Zacks
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
